Clincosm LogoSign in Get a demo

C-Reactive Protein/Albumin Ratio and Acne Vulgaris

Sponsor
Ataturk University (Other)
Overall Status
Completed
CT.gov ID
NCT06004583
Collaborator
(none)
96
Enrollment
1
Location
15.8
Actual Duration (Months)
6.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Objective: Acne vulgaris, an inflammatory disease, was investigated in this study with the claim that C-reactive protein (CRP) / albumin ratio and some hematological parameter ratios have the potential to be used as inflammatory markers to monitor disease severity and prognosis.

Methods: A descriptive cross-sectional study was conducted with two groups of patients aged 18-65 years, 61 patients diagnosed with acne vulgaris and 35 healthy control patients, and routine hemogram and biochemical parameters were compared. The Global Acne Severity Index was used to determine the severity of acne vulgaris.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Biochemical blood analysis

Study Design

Study Type:
Observational
Actual Enrollment :
96 participants
Observational Model:
Case-Control
Time Perspective:
Retrospective
Official Title:
Relationships Between Disease Severity and The C-Reactive Protein/Albumin Ratio and Various Hematological Parameters in Patients With Acne Vulgaris
Actual Study Start Date :
Jan 5, 2022
Actual Primary Completion Date :
Feb 2, 2023
Actual Study Completion Date :
May 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Acne group

Acne Vulgaris Diagnosed Patients

Diagnostic Test: Biochemical blood analysis
Serum CRP and albumin levels
Control group

Healthy participants

Diagnostic Test: Biochemical blood analysis
Serum CRP and albumin levels

Outcome Measures

Primary Outcome Measures

  1. CRP/albumin ratio [3 months]

    Statistical difference between groups

Secondary Outcome Measures

  1. Usage of CRP/albumin ratio as a Biomarker [3 months]

    New detection of CRP/albumin ratio as a new biomarker in the Acne patients

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 40 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

  • Acne vulgaris patients diagnosed by a dermatologist

  • Healthy participants without acne

  • 18-40 years of age

  • Voluntary participation

Exclusion Criteria:

  • Aged below18 or above 40 years

  • Not voluntarily participated patents

  • Pregnants, breast milked mothers, emergency situations

Contacts and Locations

Locations

Site City State Country Postal Code
1 AtaturkU Erzurum Turkey

Sponsors and Collaborators

  • Ataturk University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Erdal Pala, Ass.Prof, Ataturk University
ClinicalTrials.gov Identifier:
NCT06004583
Other Study ID Numbers:
  • 30.12.2021/567
First Posted:
Aug 22, 2023
Last Update Posted:
Aug 22, 2023
Last Verified:
Aug 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Erdal Pala, Ass.Prof, Ataturk University
acne vulgaris
CRP albumin ratio
Additional relevant MeSH terms:
Acne Vulgaris

Study Results

No Results Posted as of Aug 22, 2023